• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Oncology

SHISA3 is epigenetically silenced and its ectopic expression suppresses growth in breast cancer

byDavy LauandAlex Chan
July 29, 2020
in Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. The SHISA3 gene was found to be silenced through promoter methylation at higher levels in breast cancer tissues compared to normal breast tissues.

Evidence Rating Level: 1 (Excellent)

Breast cancer (BC) accounts for 15% of tumor related deaths in women, translating to over 627,000 deaths worldwide in 2018 alone. Late diagnosis is considered to be a primary reason for high BC mortality rates, which can be attributed to a scarcity of reliable biomarkers for early stage diagnosis. On the molecular scale, the Wnt signalling pathway plays a role in mammary gland development, with Wnt proteins controlling the growth of ducts in mammary tissue. As well, abnormal activation of this pathway has been correlated to BC development, and so has stabilization of β-Catenin, a regulator of this pathway. SHISA3 is a potential tumour suppressor gene, with the SHISA3 protein acting as an antagonist to Wnt/β-catenin signalling. Epigenetic inactivation of SHISA3 has been found in laryngeal squamous cell and nasopharyngeal carcinoma, though it has not been thoroughly investigated in BC. The current study aimed to investigate SHISA3 gene expression levels in BC cell lines and tissues, as a reduction in SHISA3 expression may provide a biological mechanism for BC development. Three BC cell lines, as well as BC and normal breast tissue samples from 103 patients, were examined in this study. The results found that mRNA levels of SHISA3 were significantly lower in BC tissues than normal breast tissues, as much as 22 times lower in the invasive ductal carcinoma subtype. Additionally, the promoter of SHISA3 was found to be methylated at higher rates in BC tissues than normal tissues (61% vs 18% of samples respectively). Methylation of the promoter was experimentally found to effectively silence the SHISA3 gene. Furthermore, ectopic expression of SHISA3 was shown to substantially reduce the migration ability and proliferative potential of these cells. Study findings appear to identify SHISA3 as a tumour suppressor gene that may have powerful therapeutic implications in BC.

Click to read the study in PlosONE

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

Daraxonrasib extends survival in metastatic pancreatic cancer

Tags: Breast Cancergeneticsoncologyscreening
Previous Post

SHISA3 is epigenetically silenced and its ectopic expression suppresses growth in breast cancer

Next Post

No association between influenza vaccine exposure in utero and adverse childhood health outcomes

RelatedReports

Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
Oncology

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

October 5, 2026
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Oncology

Historical redlining associated with lower breast cancer screening across urban neighborhoods

September 13, 2026
Next Post
Influenza vaccine not associated with increased risk of epilepsy in children

No association between influenza vaccine exposure in utero and adverse childhood health outcomes

#VisualAbstract: Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19

#VisualAbstract: Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19

A sibling-adoption design for the study of genetic and environmental influence on children’s body mass index #TA

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Children with intellectual and developmental disabilities have increased risks of depression and anxiety
  • Gabapentin (Neurontin) prescription for chronic low back pain in adults is associated with a higher risk of dementia
  • The rate of urethrocutaneous fistula formation may be similar between caudal and penile blocks
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.